Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Henderson Global Investors
AddedFeb 13, 2024
UpdatedJul 16, 2026
Henderson Global Investors

Henderson Global Investors

Acquired

Janus Henderson: A British-American global investment manager offering diverse financial products worldwide.

Location
London, Greater London, GB
Founded
1934
Firm
Compare
Portfolio
Fundraising
Employees
Website

Investments

Claris Biotherapeutics
Claris Biotherapeutics

Total Raised

$101.5M

Rounds

3

Series A$57MJanuary 2024
Parse Biosciences
Parse Biosciences

Total Raised

$100M

Rounds

6

Series C$50MDecember 2023
Series B$41.5MFebruary 2022
Bicara Therapeutics
Bicara Therapeutics

Total Raised

$313M

Rounds

3

Series C$165MDecember 2023
Series B$108MMarch 2023
Benitec Biopharma
Benitec Biopharma
Public

Total Raised

$82.3M

Rounds

7

Post Ipo Equity$3MAugust 2023
Immunome
Immunome
Public

Total Raised

$218.9M

Rounds

20

Post Ipo Equity$125MJune 2023
Carmot Therapeutics
Carmot Therapeutics

Total Raised

$384.8M

Rounds

8

Series E$150MMay 2023
Heartflow
Heartflow

Total Raised

$792.7M

Rounds

11

Series F$215MApril 2023
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023
Series A$125MNovember 2021
Via
Via

Total Raised

$887.1M

Rounds

9

Series Unknown$110MFebruary 2023
Series G$130MNovember 2021
Entact Bio
Entact Bio

Total Raised

$120.9M

Rounds

2

Series A$81MDecember 2022
Curevo
Curevo

Total Raised

$86M

Rounds

2

Series A$26MNovember 2022
Series A$60MJanuary 2022
Elektrofi
Elektrofi

Total Raised

$41.9M

Rounds

3

Series B$40MJune 2022
IntelyCare
IntelyCare

Total Raised

$170.8M

Rounds

3

Series C$115MApril 2022
2seventy bio
2seventy bio
Public

Total Raised

$315M

Rounds

4

Post Ipo Equity$170MMarch 2022
Magnolia Medical Technologies
Magnolia Medical Technologies

Total Raised

$117.3M

Rounds

9

Series Unknown$46MFebruary 2022
Inspirato
Inspirato
Public

Total Raised

$204.7M

Rounds

8

Post Ipo Equity$100MFebruary 2022
Ceptur Therapeutics
Ceptur Therapeutics

Total Raised

$81.2M

Rounds

2

Series A$75MJanuary 2022
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
P3 Health Partners
P3 Health Partners
Public

Total Raised

$290M

Rounds

3

Post Ipo Equity$200MDecember 2021
Arbor Biotechnologies
Arbor Biotechnologies

Total Raised

$230.6M

Rounds

2

Series B$215MNovember 2021